AbbVievsOmeros

ABBV and OMER stock compared: price, dividend, valuation and results, from SEC filings.

AbbVie (ABBV) has a market value of $518B and Omeros (OMER) $1.0B. Over the last year, with dividends, ABBV moved +29.8% and OMER +76.9%. The P/E is 50.3 for ABBV and 10.2 for OMER. Dividend yield: ABBV 2.36%, OMER none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$518B

    OMER$1.0B

    ABBV is 517 times OMER

  • Revenue, 12 months

    ABBV$66.0B

    OMER–

  • Net income, 12 months

    ABBV$10.3B

    OMER$98M

    ABBV is 105 times OMER

  • Operating margin

    ABBV32.2%

    OMER–

  • ROIC

    ABBV25.7%

    OMER–

  • P/E

    ABBV50.3

    OMER10.2

    ABBV is 4.9 times OMER

  • Dividend yield

    ABBV2.4%

    OMER0.0%

    2.4 points apart

  • 5-year return

    ABBV+200.7%

    OMER+68.9%

    131.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+200.7%

OMER+68.9%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsOMERWith dividends
1 year since November 14, 2025+29.8%Price +26.0%+76.9%Price +76.9%
3 years since November 17, 2023+134.1%+32.8% a yearPrice +111.7%+748.8%+104.0% a yearPrice +748.8%
5 years since November 16, 2021+200.7%+24.6% a yearPrice +151.5%+68.9%+11.1% a yearPrice +68.9%
10 years since November 17, 2016+613.5%+21.7% a yearPrice +374.6%+5.1%+0.5% a yearPrice +5.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieOMEROmeros

Valuation

ABBVOMER
Valuation
Price$292.82$13.92
Market value$518B$1.0B
Enterprise value (EV)$588B–
P/E50.310.2
P/E, 5-year median57.0–
P/B––
EV/EBIT27.7–
Free cash flow yield3.6%–

Results and growth

ABBVOMER
Results and growth
Revenue, 12 months$66.0B–
Net income, 12 months$10.3B$98M
Free cash flow, 12 months$18.9B-$37M
Earnings per share, 12 months$5.81$1.37
Revenue growth, year on year8.6%-34.0%
Revenue growth a year, past+5.9%over 5 years+15.4%over 4 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVOMER
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%–
Net margin15.7%–
ROIC25.7%–
ROE––

Balance sheet

ABBVOMER
Balance sheet
Cash$10.8B$95M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×-4.3×

Dividends and buybacks

ABBVOMER
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or OMER

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Omeros?

By market value, AbbVie ($518B) is about 516.6 times Omeros ($1.0B), at today's prices.

How did ABBV and OMER stock do over the last 10 years?

Since November 17, 2016, ABBV's price moved +374.6% and OMER's +5.1%. With dividends: ABBV +613.5% (+21.7% a year), OMER +5.1% (+0.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or OMER?

The dividend yield at today's price is 2.36% for AbbVie and none for Omeros. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and OMER?

At today's price, the P/E is 50.3 for ABBV and 10.2 for OMER. It is the share price over the last twelve months' earnings per share.

Which is the better investment, AbbVie or Omeros?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.